Be the first person to write a business review for Advion, Inc.

The biopharmaceutical company develops cholesterol-lowering drugs for the treatment of cardiovascular and metabolic disease, specifically targeting elevated LDL (low-density lipoprotein, also known as "bad" cholesterol) levels. Its flagship products - experimental drugs AEGR-733 and AEGR-427 - are MTP (microsomal triglyceride transfer protein) inhibitors, drugs which block a protein that incites cholesterol production in the liver and intestine. Cutting LDL levels may add years to patients' lives but must be weighed against potential side effects such as fat accumulation in the liver, which can lead to inflammation, scarring, and cirrhosis.

AERES Biomedical Ltd. company was founded in 1999. AERES Biomedical develops therapeutic antibodies. The biopharmaceutical research company has developed more than 20 antibody candidates though collaborative partnerships with other biotech and pharmaceutical companies, many of which are in clinical trial stages. ABC-48 (an antibody for the treatment of deep vein thrombosis) and ABC-120 (an antibody for treating malaria) are two of the company's top candiates. AERES' products target debilitating and life-threatening illnesses, such as infectious, inflamatory, and cardiovascular diseases.

AES Laboratoire produces and distributes a complete range of microbial testing instruments and equipment. Whether for quality assurance or national security, clients from 21 countries in industries from food production to pharmaceuticals contract with AES to assure the quality and safety of products and to monitor possible hazards in various working environments. AES is developing and patenting technologies that are more accurate and less time-consuming than traditional laboratory testing methods, including machines that sample the air for bio-contaminants and chemical "litmus tests" that can quickly detect and identify pathogens.

Afexa Life Sciences (formerly CV Technologies) bets that mother nature is always right, but it offers a guarantee just in case. The company uses its ChemBioPrint technology to identify and measure the contents and biological activity of natural health products to ensure batches of herbs and natural compounds are safe and consistent. The company originated as a spin-off from the Faculty of Medicine at the University of Alberta in 1992, and now focuses on the development and manufacturing of natural health products for disease prevention and health maintenance for everyday consumers, especially athletes. COLD-fX is Afexa's lead product and works to strengthen the immune system to prevent colds and the flu.

Affymax, Inc. company was founded in 2001 and is based in Palo Alto, California. Affymax, Inc., a biopharmaceutical company, engages in the development of peptide-based drug candidates to enhance the treatment of serious and life-threatening conditions. The company’s lead product candidate, Hematide, is designed to treat anemia associated with chronic renal failure. Hematide is a synthetic peptide-based erythropoiesis stimulating agent designed to stimulate production of red blood cells. It is conducting Phase III clinical trials for the treatment of anemia associated with chronic renal failure, on dialysis, and pre-dialysis. Affymax has a license, manufacturing, and supply agreement with Nektar Therapeutics AL, Corporation to manufacture, develop, and commercialize Hematide.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.